Life Member: NY State Medical Society
Web Strategy Committee for American Society of Lasers in Medicine & Surgery 2017
Scientific Advisory Board – American Council Science & Health 2016
Founding Member, 2015 International Dermal Ultrasound Society
Member, Greater NY Dermatology Society 2015
Founding Member, 2014 American Cutaneous Cancer Society
American Society Lasers in Medicine & Surgery 2014-present
European Society of Radiology 2014
Member, Mt Sinai Melanoma Group 2013
Click HERE for complete list of Associations
Communication Representative, American Institute of Ultrasound in Medicine 2012
Visiting Professor Service d’Oncologie, Hopital Pitie-Salpetriere Paris, 2008
Visiting Professor Dept. of Dermatology, Mount Sinai Medical School 2007
International HIFU Society 2006
Societe d’Imagerie Ultrasonore 2005
Prostate Cancer Focused Ultrasound Certification 2005, US HIFU Prostate Institute
Visiting Professor Dept of Urology 2004, Maimonides Hospital of Mt Sinai Med School
Founder, Biofoundation for Angiogenesis Research 2001
Societe Francaise de Radiologie 2001
Key Speaker Foot and Ankle Ultrasound Colorado Podiatric Medical Association Steamboat Springs 2000
President, Tendon Ultrasound Section, 5th International Congress of Musculoskeletal
Sonography Prague 2000
NY Metropolitan Breast Cancer Group 1999
International Cancer Imaging Society 1998
Director, Robert Bard MD PC 1994-present
2017 DEMUS GROUP teaching presentation on skin cancer imaging at the world conference Americal Institute of Ultrasound Medicine- Orlando, Fla. March, 2017
Did You Know…
Dr. Bard is the only American member of the International Dermal Ultrasound Group with physicians selected from 12 participating nations worldwide. (Visit our expanded NEWS section)
NON-INVASIVE PROSTATE CANCER DIAGNOSIS
Until recently, standard prostate cancer screening consisted of a PSA blood test (Prostate Specific Antigen) and DRE (Digital Rectal Exam). In 2017 a U.S. Government Panel released a statement suggesting such screening had a high cost with doubtful survival advantage. In other words, too many men whose screening revealed a suspiciously high PSA or abnormal DRE were rushed into multi-needle biopsies that entailed risks of false negatives, infection, and sexual side effects. (MORE)
BARD CANCER DIAGNOSTICS is founded on the commitment to explore and implement the latest diagnostic technologies as a means of building the proper treatment strategy of many types of cancers. We also specialize in the PREVENTION solutions for our patients who strive to maintain a health-conscious lifestyle as well as those who are at increased risk of certain diseases by confirming that their efforts to prevent disease are working.
BARD CANCER DIAGNOSTICS
121 E. 60th St. Suite #6A New York, NY 10022
212.355.7017
Info@bardcancercenter.com